Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Resumen detallado

Regeneron's earnings have climbed thanks to this portfolio, and the company also has a solid pipeline to support future earnings growth. Today, with $16 billion in cash and…

Commercial-stage biotech companies make great investments for those of us looking for both safety and growth. Their portfolios of commercialized products offer a certain degree of revenue stability since patients always need their medicines, regardless of the economic situation. And biotech companies' focus on innovation provides us with the potential for significant growth.

Regeneron Pharmaceuticals (NASDAQ: REGN) is one of these players, and shareholders have reaped the rewards over the past year: The stock climbed more than 40%. The company has 16 approved or authorized products in the U.S. and other countries, and these include treatments in immunology, ophthalmology, and oncology.

Missed AI's "Act 1"? Act 2 Could Be 16x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we're only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Regeneron's earnings have climbed thanks to this portfolio, and the company also has a solid pipeline to support future earnings growth. Today, with $16 billion in cash and trading around 20x earnings, is Regeneron the cheapest big biotech? Let's find out.

Regeneron has been around for nearly 40 years, and since that time has innovated across many treatment areas. Its products have helped revenue and net income advance over time; earnings reached a peak a few years ago as sales of Regeneron's coronavirus antibody cocktail soared and as other leading products generated growth.

In more recent times, Regeneron's top-selling eye drug Eylea has seen sales decrease due to competition -- but there's a silver lining in this dark cloud. The company's Eylea HD, an updated, higher-dose formula, is taking some of that market share and represents a fresh growth driver. Meanwhile, immunology drug Dupixent -- sold in partnership with Sanofi -- and cancer drug Libtayo are also driving gains.

And in the most recent quarter, Regeneron's earnings figures and…

S…

Inicio del artículo, extracto de Yahoo Finance. Para leer el resto, abra el artículo en el sitio del medio.